Loading clinical trials...
Loading clinical trials...
Develop adverse event prediction and plaque phenotype classification models for patients with known or suspected carotid artery disease.
Develop adverse event prediction and plaque phenotype classification models using plaque morphology and composition assessment of CTA which has been validated by histology, applied to representative cohort of patients. Generalizability of models is enhanced by using validated rather than only raw image inputs. Demographic, clinical, and outcome data is collected for enrolled patients as well as information on events and interventions.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Baltimore VA Medical Center
Baltimore, Maryland, United States
University of Maryland, Baltimore
Baltimore, Maryland, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
Weill Cornell Medicine (Affiliated with New York Presbyterian Hospital)
New York, New York, United States
University Hospital Harrington (Affiliated with Case Western Reserve University)
Cleveland, Ohio, United States
Start Date
March 1, 2019
Primary Completion Date
December 15, 2021
Completion Date
April 30, 2022
Last Updated
February 4, 2021
800
ESTIMATED participants
vascuCAP
DIAGNOSTIC_TEST
Lead Sponsor
Elucid Bioimaging Inc.
Collaborators
NCT06214429
NCT06541691
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06253962